CSA Medical said today that results of its feasibility study into the RejuvenAir metered cryospray system showed improved quality of life in patients who have chronic obstructive pulmonary disease with chronic bronchitis.
The one-year study treated 35 patients using metered cryospray with the RejuvenAir system that is designed to apply spray-liquid nitrogen at -196◦C in a circumferential pattern to central airways through a minimally invasive bronchoscopic procedure, freezing damaged surface area lung cells to for a rejuvenating healing process.
The data presented displayed clinically significant improvements in multidimensional measures of cough, sputum production, breathlessness and quality of life, according to a news release. Lexington, Mass.-based CSA Medical said the quality of life scores were superior to the pharmacologic standard of care.
The results were presented by CSA Medical at the 2019 European Respiratory Society International Congress in Madrid. CSA Medical touted similar quality of life results with the RejuvenAir system at last year’s ERS International Congress in Paris.
“Metered Cryospray appears to have a beneficial response with a decrease in cough and mucus production even in our patients who had optimized medical management,” University Medical Center, Groningen, The Netherlands’ Dr. Jan Slebos said in prepared remarks. “The overall improvement in breathing resulted in increased physical activity supporting the potential for RejuvenAir to measurably improve quality of life in chronic bronchitis patients.”
The RejuvenAir system is still under clinical investigation the U.S. The company has raised nearly $75 million over the past 12 months in funding, pulling in $23 million in October 2018, then grabbing $50.3 million in separate equity and debt rounds.